Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKBA Akebia Therapeutics	$3.61 -0.7%	$3.11	$0.91 ▼ $4.08	$950.74M	0.88	3.15 million shs	1.57 million shs
ETNB 89BIO	$10.14 +0.4%	$9.26	$4.16 ▼ $11.84	$1.48B	1.28	1.52 million shs	1.94 million shs
FBIO Fortress Biotech	$1.91 +4.3%	$1.82	$1.33 ▼ $2.89	$55.59M	1.75	411,063 shs	180,983 shs
FBRX Forte Biosciences	$13.81 -0.2%	$9.88	$4.11 ▼ $28.68	$89.93M	2.97	172,477 shs	23,706 shs
VSTM Verastem	$4.76 -1.9%	$6.36	$2.10 ▼ $9.10	$263.76M	0.71	1.26 million shs	1.68 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKBA Akebia Therapeutics	0.00%	-1.23%	-0.96%	+103.67%	+280.88%
ETNB 89BIO	0.00%	+2.84%	+0.80%	+75.74%	+35.56%
FBIO Fortress Biotech	0.00%	+4.89%	+3.19%	+25.59%	+8.47%
FBRX Forte Biosciences	0.00%	+12.73%	+38.38%	+134.86%	+67,782.42%
VSTM Verastem	0.00%	+14.70%	-22.85%	-7.75%	+61.90%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKBA Akebia Therapeutics	4.2685 of 5 stars	3.6	4.0	4.0	2.0	0.8	0.6
ETNB 89BIO	1.9454 of 5 stars	3.5	1.0	0.0	2.3	0.8	0.6
FBIO Fortress Biotech	2.1667 of 5 stars	3.5	1.0	0.0	0.6	3.3	0.6
FBRX Forte Biosciences	2.5698 of 5 stars	3.5	4.0	0.0	0.6	1.7	0.6
VSTM Verastem	2.6456 of 5 stars	3.5	3.0	0.0	1.0	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKBA Akebia Therapeutics	3.20	Buy	$6.75	87.24% Upside
ETNB 89BIO	3.00	Buy	$26.43	160.64% Upside
FBIO Fortress Biotech	3.00	Buy	$21.00	1,000.05% Upside
FBRX Forte Biosciences	3.00	Buy	$61.00	341.71% Upside
VSTM Verastem	3.00	Buy	$13.38	180.99% Upside

Current Analyst Ratings Breakdown

Latest AKBA, VSTM, FBIO, FBRX, and ETNB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	ETNB 89BIO	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
6/25/2025	VSTM Verastem	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$16.00 ➝ $12.00
6/24/2025	FBRX Forte Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$61.00
6/11/2025	ETNB 89BIO	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
6/4/2025	AKBA Akebia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00
5/24/2025	ETNB 89BIO	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
5/10/2025	ETNB 89BIO	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
5/9/2025	VSTM Verastem	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $14.00
4/30/2025	ETNB 89BIO	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/28/2025	AKBA Akebia Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/28/2025	AKBA Akebia Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$7.00

(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKBA Akebia Therapeutics	$160.18M	5.91	N/A	N/A	($0.23) per share	-15.67
ETNB 89BIO	N/A	N/A	N/A	N/A	$3.34 per share	N/A
FBIO Fortress Biotech	$57.67M	0.98	N/A	N/A	($0.06) per share	-31.82
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	$8.21 per share	N/A
VSTM Verastem	$10K	26,156.20	N/A	N/A	($0.65) per share	-7.32

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKBA Akebia Therapeutics	-$69.41M	-$0.21	N/A	N/A	N/A	-24.51%	N/A	-18.92%	8/6/2025 (Estimated)
ETNB 89BIO	-$367.08M	-$3.38	N/A	N/A	N/A	N/A	-81.44%	-70.17%	8/4/2025 (Estimated)
FBIO Fortress Biotech	-$46M	-$2.23	N/A	N/A	N/A	-71.24%	-4,712.53%	-27.67%	8/12/2025 (Estimated)
FBRX Forte Biosciences	-$35.48M	-$16.29	N/A	N/A	N/A	N/A	-149.15%	-114.25%	8/13/2025 (Estimated)
VSTM Verastem	-$130.64M	-$3.20	N/A	N/A	N/A	N/A	-2,003.62%	-127.97%	8/6/2025 (Estimated)

Latest AKBA, VSTM, FBIO, FBRX, and ETNB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	FBRX Forte Biosciences	-$0.89	-$1.37	-$0.48	-$1.37	N/A	N/A
5/13/2025	Q1 2025	VSTM Verastem	-$0.72	-$0.96	-$0.24	-$0.96	$0.10 million	N/A
5/8/2025	Q1 2025	AKBA Akebia Therapeutics	-$0.03	$0.03	+$0.06	$0.03	$44.88 million	$57.34 million
5/1/2025	Q1 2025	ETNB 89BIO	-$0.50	-$0.49	+$0.01	-$0.49	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKBA Akebia Therapeutics	N/A	N/A	N/A	N/A	N/A
ETNB 89BIO	N/A	N/A	N/A	N/A	N/A
FBIO Fortress Biotech	N/A	N/A	N/A	N/A	N/A
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	N/A
VSTM Verastem	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKBA Akebia Therapeutics	1.89	2.23	2.02
ETNB 89BIO	0.06	18.03	18.03
FBIO Fortress Biotech	1.74	1.72	1.55
FBRX Forte Biosciences	N/A	5.22	5.22
VSTM Verastem	N/A	3.50	3.50

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKBA Akebia Therapeutics	33.92%
ETNB 89BIO	N/A
FBIO Fortress Biotech	96.51%
FBRX Forte Biosciences	77.63%
VSTM Verastem	88.37%

Insider Ownership

Company	Insider Ownership
AKBA Akebia Therapeutics	3.00%
ETNB 89BIO	2.60%
FBIO Fortress Biotech	27.90%
FBRX Forte Biosciences	5.90%
VSTM Verastem	2.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKBA Akebia Therapeutics	430	262.64 million	254.76 million	Optionable
ETNB 89BIO	40	145.98 million	142.19 million	Optionable
FBIO Fortress Biotech	170	29.57 million	21.32 million	Optionable
FBRX Forte Biosciences	5	6.58 million	6.20 million	Optionable
VSTM Verastem	50	54.95 million	53.80 million	Optionable

AKBA, VSTM, FBIO, FBRX, and ETNB Headlines

Recent News About These Companies

BTIG Remains a Buy on Verastem (VSTM)

July 4 at 2:22 PM | theglobeandmail.com

Verastem’s Phase 3 Study on Avutometinib and Defactinib: A Potential Game-Changer for Ovarian Cancer Treatment

July 4 at 12:13 PM | tipranks.com

Analysts Set Verastem, Inc. (NASDAQ:VSTM) Target Price at $13.38

July 1, 2025 | americanbankingnews.com

Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer

June 30, 2025 | businesswire.com

Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Recommendation of "Buy" from Brokerages

June 28, 2025 | marketbeat.com

Cantor Fitzgerald Reduces Earnings Estimates for Verastem

June 28, 2025 | americanbankingnews.com

Verastem (NASDAQ:VSTM) Stock Rating Upgraded by Royal Bank Of Canada

June 27, 2025 | americanbankingnews.com

Verastem: Approval Secured, Moving On To PDAC And KRAS G12D-Related Cancers

June 26, 2025 | seekingalpha.com

FY2025 EPS Estimates for Verastem Cut by Cantor Fitzgerald

June 26, 2025 | marketbeat.com

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors - Morningstar

June 26, 2025 | morningstar.comM

Royal Bank Of Canada Has Lowered Expectations for Verastem (NASDAQ:VSTM) Stock Price

June 25, 2025 | marketbeat.com

Insider Sell Alert: Daniel Calkins Sells Shares of Verastem Inc (VSTM)

June 24, 2025 | gurufocus.com

Verastem, Inc. (NASDAQ:VSTM) CFO Daniel Calkins Sells 4,110 Shares

June 24, 2025 | marketbeat.com

Dan Paterson Sells 17,808 Shares of Verastem, Inc. (NASDAQ:VSTM) Stock

June 24, 2025 | marketbeat.com

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors

June 24, 2025 | businesswire.com

Verastem’s SWOT analysis: biotech stock poised for growth amid challenges

June 15, 2025 | investing.com

Verastem reports promising cancer drug trial results

June 3, 2025 | investing.com

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor

June 3, 2025 | businesswire.com

Verastem’s Promising Clinical Advances and Strategic Developments Justify Buy Rating

June 3, 2025 | tipranks.com

Verastem Announces Positive Data From Cancer Trial Conducted By Partner: Retail Turns Bullish

June 2, 2025 | msn.com

Verastem Announces Strategic Plans in Investor Webcast

June 2, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKBA, VSTM, FBIO, FBRX, and ETNB Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

$3.60 -0.03 (-0.69%)

Closing price 07/3/2025 02:45 PM Eastern

Extended Trading

$3.62 +0.01 (+0.28%)

As of 07/3/2025 04:58 PM Eastern

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

89BIO NASDAQ:ETNB

$10.14 +0.04 (+0.40%)

Closing price 07/3/2025 02:41 PM Eastern

Extended Trading

$10.14 -0.01 (-0.05%)

As of 07/3/2025 04:20 PM Eastern

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

Fortress Biotech NASDAQ:FBIO

$1.91 +0.08 (+4.32%)

As of 07/3/2025 03:36 PM Eastern

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Forte Biosciences NASDAQ:FBRX

$13.81 -0.03 (-0.22%)

Closing price 07/3/2025 03:25 PM Eastern

Extended Trading

$13.02 -0.80 (-5.76%)

As of 07/3/2025 04:40 PM Eastern

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Verastem NASDAQ:VSTM

$4.76 -0.09 (-1.86%)

Closing price 07/3/2025 03:44 PM Eastern

Extended Trading

$4.76 0.00 (0.00%)

As of 07/3/2025 04:45 PM Eastern

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time